Non-small cell lung cancer stage IV

41 trials 12 recruiting MedDRA PT
41 Registered trials
12 Recruiting
29 Unique sponsors
52 Unique IMPs
30 Commercial trials
Drug classes (ATC)
— ATC code not specified 17
N Neurology/Psychiatry (ATC N) 3
L Oncology (ATC L) 22
Mechanism of action (INN-stem analysis)
Unknown / small molecule 14 substances
Kinase inhibitor 12 substances
Monoclonal antibody (immune) 4 substances
Antimetabolite 3 substances
Checkpoint inhibitor (PD-1) 2 substances
Antibody-drug conjugate (ADC) 2 substances
Platinum compound 2 substances
Taxane 2 substances
Checkpoint inhibitor (PD-L1) 2 substances
PARP inhibitor 2 substances
RAF/BRAF inhibitor 2 substances
Monoclonal antibody 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
BCL-2 inhibitor 1 substance
Vinca alkaloid 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase III: 8 Phase II/III: 1 Phase II: 19 Phase I/II: 5 Phase I: 1 Phase I (Other): 4 Phase I (First in Human): 3

Filter these 41 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 41 trials

Phase III

8 trials
  • Bio-Thera Solutions Ltd. Commercial
    CARBOPLATIN; PEMBROLIZUMAB; PEMETREXED
    2024-510640-32-00 1 country 2024 n=23
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    CISPLATIN; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMETREXED
    2023-508757-75-00 7 countries 2017 n=456
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ALECTINIB; ALECTINIB HYDROCHLORIDE; ATEZOLIZUMAB; CABOZANTINIB; COBIMETINIB; NIRAPARIB; PACLITAXEL; PEMETREXED; SUNITINIB; VEMURAFENIB; VENETOCLAX
    2023-506184-34-00 11 countries 2019 n=104 Orphan
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    NIRAPARIB TOSILATE MONOHYDRATE; PEMBROLIZUMAB
    2023-508443-40-00 14 countries 2020 n=363 Orphan
    Ended
  • Maia Biotechnology Inc. Commercial
    2-AMINO-9-((2R,4R,5R)-4-HYDROXY-5-(HYDROXYMETHYL) TETRAHYDROFURAN-2-YL)-1,4,5,9-TETRAHYDRO-6H-PURINE-6-THIONE; CEMIPLIMAB; DOCETAXEL; GEMCITABINE; VINORELBINE
    2024-520164-33-00 4 countries 2025 n=105
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-508308-40-00 5 countries 2021 n=215
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-509169-19-00 8 countries 2017 n=33
    Ended
  • Xcovery Holding Co. LLC Commercial
    CRIZOTINIB; X-396
    2024-513454-29-00 7 countries 2015 n=47
    Ended

Phase II/III

1 trial
  • BioNTech SE Commercial
    BISPECIFIC ANTIBODY AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR A AND PROGRAMMED DEATH-LIGAND 1; BNT327
    2024-515764-31-00 9 countries 2025 n=726
    Recruiting

Phase II

19 trials
  • Amgen Inc. Commercial
    IMP not specified
    2024-511189-36-00 5 countries 2021 n=23
    Ended
  • Bicycletx Limited Commercial
    ZELENECTIDE PEVEDOTIN
    2025-521115-40-00 4 countries 2025 n=28
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    BMS-986315; NIVOLUMAB
    2022-503007-22-00 5 countries n=95
    Ended
  • Celgene Corp. Commercial
    AZACITIDINE
    2024-513405-31-00 1 country 2015 n=1
    Ended
  • Incyte Corp. Commercial
    INCB099280
    2022-502716-37-00 3 countries 2023 n=70
    Ended
  • Janssen - Cilag International Commercial
    AMIVANTAMAB; LAZERTINIB
    2025-520730-28-00 9 countries 2025 n=118
    Recruiting
  • Maia Biotechnology Inc. Commercial
    2-AMINO-9-((2R,4R,5R)-4-HYDROXY-5-(HYDROXYMETHYL) TETRAHYDROFURAN-2-YL)-1,4,5,9-TETRAHYDRO-6H-PURINE-6-THIONE; CEMIPLIMAB
    2023-504595-26-00 4 countries 2023 n=222
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    FAVEZELIMAB; LENVATINIB; PEMBROLIZUMAB; QUAVONLIMAB
    2022-500990-16-00 3 countries 2018 n=84
    Ended
  • Merck Sharp & Dohme LLC Commercial
    IFINATAMAB DERUXTECAN; RALUDOTATUG DERUXTECAN
    2024-518839-11-00 6 countries 2025 n=66
    Recruiting
  • Seagen Inc. Commercial
    PEMBROLIZUMAB; TISOTUMAB VEDOTIN
    2023-503812-34-00 4 countries 2019 n=79
    Ended
  • AIO-Studien gGmbH Academic
    OSIMERTINIB
    2022-503028-29-01 1 country 2021 n=40
    Ended
  • Centro Di Riferimento Oncologico Di Aviano Academic
    CARBOPLATIN; CISPLATIN; LORLATINIB; PEMETREXED
    2023-506714-43-00 1 country 2024 n=45
    Recruiting
  • Heidelberg University Academic
    OSIMERTINIB
    2024-516790-78-00 1 country 2025 n=40
    Recruiting
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    ATEZOLIZUMAB
    2022-502103-30-00 1 country 2023 n=156
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    BRIGATINIB; CARBOPLATIN; PEMETREXED
    2023-510387-13-00 1 country 2022 n=110
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    LORLATINIB
    2024-512028-12-00 1 country 2021 n=84
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    DURVALUMAB
    2024-515943-44-00 1 country 2020 n=50
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    BINIMETINIB; ENCORAFENIB
    2024-515944-22-00 1 country 2021 n=119
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    IMP not specified
    2025-522790-10-00 1 country n=108
    Pending

Phase I/II

5 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BUDIGALIMAB; CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; TELISOTUZUMAB ADIZUTECAN
    2024-514465-18-00 7 countries 2025 n=96
    Recruiting
  • BioNTech SE Commercial
    BNT326; BNT327
    2024-519344-32-00 4 countries 2026 n=88
    Recruiting
  • BioNTech SE Commercial
    BNT324; BNT327
    2024-520238-31-01 4 countries 2026 n=112 Orphan
    Recruiting
  • Galecto Biotech AB Commercial
    5-BROMOPYRIDIN-3-YL 3-DEOXY-1-THIO-3-[4-(3,4,5-TRIFLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL]-ALFA-D-GALACTOPYRANOSIDE; ATEZOLIZUMAB
    2024-514419-93-00 2 countries 2022 n=49
    Ended
  • Incyte Corp. Commercial
    ADAGRASIB; INCB099280
    2023-503223-26-00 3 countries 2024 n=75
    Ended

Phase I

1 trial

Phase I (Other)

4 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2024-511956-42-00 1 country 2019 n=44
    Ended
  • Exelixis Inc. Commercial
    IMP not specified
    2024-516477-73-00 2 countries 2018 n=320
    Ended
  • Systimmune Inc. Commercial
    IMP not specified
    2023-506539-14-00 3 countries 2025 n=95
    Recruiting
  • TOLREMO therapeutics AG Commercial
    IMP not specified
    2024-519071-25-00 1 country n=40
    Pending

Phase I (First in Human)

3 trials
  • Achilles Therapeutics UK Limited Commercial
    ATL001; PEMBROLIZUMAB
    2024-513060-26-00 3 countries 2021 n=24
    Ended
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Inhatarget Therapeutics Academic
    IMP not specified
    2022-501183-17-00 3 countries 2023 n=64
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Intergroupe Francophone De Cancerologie Thoracique Academic 6 Phase II 0
BioNTech SE Commercial 3 Phase II/III, Phase I/II 3
Incyte Corp. Commercial 3 Phase II, Phase I/II, Phase I 0
Merck Sharp & Dohme LLC Commercial 3 Phase II, Phase III 1
Maia Biotechnology Inc. Commercial 2 Phase II, Phase III 2
AstraZeneca AB Commercial 1 Phase I (Other) 0
Exelixis Inc. Commercial 1 Phase I (Other) 0
Systimmune Inc. Commercial 1 Phase I (Other) 1
TOLREMO therapeutics AG Commercial 1 Phase I (Other) 0
Amgen Inc. Commercial 1 Phase II 0
Bicycletx Limited Commercial 1 Phase II 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase II 0
Celgene Corp. Commercial 1 Phase II 0
Janssen - Cilag International Commercial 1 Phase II 1
Seagen Inc. Commercial 1 Phase II 0
Bio-Thera Solutions Ltd. Commercial 1 Phase III 0
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase III 0
Pfizer Inc. Commercial 1 Phase III 0
New trials by year
2019
3
2020
2
2021
6
2022
3
2023
4
2024
3
2025
9
2026
2
← All indication landscapes